GHRH Antagonist MIA-602 Induces Anxiolytic, Antidepressant-Like Effects in Mice via Nrf2 and BDNF Pathways
Background
Anxiety and depression are significant risk factors for developing post-traumatic stress disorder (PTSD), and a strong link exists between these mental health conditions and underlying inflammation and oxidative stress. While existing treatments have limitations, recent research has explored novel pathways. Our group previously showed that another growth hormone-releasing hormone (GHRH) antagonist, MIA-690, has powerful anxiolytic and antidepressant-like effects. This suggests that modulating the GHRH receptor system could be a viable strategy to address mood disorders by targeting their inflammatory and oxidative components. This study investigates another GHRH antagonist, MIA-602, to see if it produces similar protective effects and to elucidate the specific brain pathways involved.
Study Design
The study investigated the effects of the GHRH antagonist MIA-602 in adult mice. The researchers used both ex vivo and in vivo experimental models to assess the compound's antioxidant and anti-inflammatory properties. For the behavioral analysis, mice were treated with subcutaneous injections of MIA-602 for 4 weeks. Following the treatment period, the animals' behavior was evaluated to measure anxiolytic and antidepressant-like responses. The researchers also examined brain tissue, specifically the hippocampus and prefrontal cortex, to identify the molecular pathways involved in any observed protective activity.
Results
MIA-602 exhibited significant anti-inflammatory and antioxidant effects in both ex vivo and in vivo models. The 4-week subcutaneous treatment regimen resulted in observable anxiolytic and antidepressant-like behavior in the adult mice. This positive behavioral outcome was linked to specific molecular changes in key brain regions.
The beneficial effects of MIA-602 on mood were associated with enhancements in both inflammatory status and synaptogenesis. These improvements appear to be mediated by the upregulation of two critical signaling pathways: the nuclear factor erythroid 2-related factor 2 (
Nrf2) pathway, a master regulator of antioxidant responses, and the brain-derived neurotrophic factor (BDNF) signaling pathway, crucial for neuronal survival and growth. These increases inNrf2andBDNFactivity were specifically observed in the hippocampus and prefrontal cortex, suggesting a targeted mechanism of action.
Key Findings
- The GHRH antagonist MIA-602 exhibited anti-inflammatory and antioxidant effects in ex vivo and in vivo models.
- Subcutaneous treatment with MIA-602 for 4 weeks induced anxiolytic behavior in adult mice.
- Subcutaneous treatment with MIA-602 for 4 weeks induced antidepressant-like behavior in adult mice.
- Protective effects were linked to increased Nrf2 signaling in the hippocampus and prefrontal cortex.
- Beneficial outcomes were associated with increased BDNF signaling in the hippocampus and prefrontal cortex.
Why It Matters
These findings suggest that GHRH receptor antagonism could be a novel and effective therapeutic strategy for mood disorders like anxiety and depression, and potentially for PTSD. For individuals exploring advanced protocols, this highlights the GHRH-R axis as a target that extends beyond growth and metabolism, influencing neuroinflammation, oxidative stress, and synaptic health. The study provides a mechanistic rationale, linking the peptide's action to Nrf2 and BDNF pathways, which are already popular targets for nootropic and anti-aging interventions. This work strongly supports the clinical investigation of GHRH antagonists for psychiatric conditions, moving them from research curiosities toward potential therapeutic tools for complex mental illnesses. While promising, this is an early-stage animal study, and human trials are needed to confirm efficacy and establish safe protocols.
